|
|
|
|
|
|
|
|
|
28.08.25 - 16:01
|
Holding(s) in Company (Cision)
|
|
|
28 August 2025
On 27 August 2025, AstraZeneca PLC (the Company) was notified by The Capital Group Companies, Inc. (Capital Group) that the TR-1 notification it submitted to the Company on 25 August 2025, and which was subsequently announced by the Company on 26 August 2025, was provided in error.
Accordingly, shareholders should disregard the TR-1 notification announced by the Company on 26 August 2025 and instead refer to the TR-1 notification in relation to Capital Group announced by the Company on 21 August 2025, which is available under RNS No. 2435W / at:
https://otp.tools....
|
|
|
27.08.25 - 10:09
|
AstraZeneca Hold (DPA-AFX)
|
|
|
FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Astrazeneca mit einem Kursziel von 11000 Pence auf "Hold" belassen. Dies schrieb Analyst Emmanuel Papadakis in seiner am Mittwoch vorliegenden Auswertung der wöchentlichen Verschreibungsdaten./ag/ajxVeröffentlichung ......
|
|
|
22.08.25 - 18:39
|
Saudi Arabia Diabetes Drug Market Trends and Company Analysis Report 2025-2033 Featuring Novo Nordisk, AstraZeneca, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Novartis - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Saudi Arabia Diabetes Drug Market Trends & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.
The Saudi Arabia Diabetes Drug Market is anticipated to grow to US$ 1.33 billion by 2033, from US$ 773.6 million in 2024, growing at a CAGR of 6.22% from 2025 to 2033
This growth is due to an increase in the prevalence of diabetes, enhanced awareness, government healthcare expenditure, and acceptance of new therapeutic agents like SGLT2 inhibitors, GLP-1 receptor agonists, and biosimilar insulins.
Diabetes medication in Saudi Arabia is experiencing growing popularity because of the prevalence of diabetes, which is largely caused by sedentary lifestyles, eating habits, and obesity. Strategic government efforts, such as Vision 2030, focus on enhanced access to healthcare and chronic disease management. The increasing number of diabetics, heightened awareness, and upgraded diagnostic facilities are driving demand for traditional as well as advanced treatmen...
|
|
|
|
|
22.08.25 - 09:12
|
AstraZeneca, Ericsson, Saab, SEB, and Wallenberg Investments launch the company Sferical AI (Cision)
|
|
|
AstraZeneca, Ericsson, Saab, SEB, and Wallenberg Investments are jointly launching the company Sferical AI, which will operate a new sovereign AI supercomputer to transform and prepare the country's leading industries for the age of AI.
This marks the next phase of the Swedish business collaboration announced by Marcus Wallenberg and NVIDIA CEO Jensen Huang in May, when Huang was awarded an honorary doctorate by Linköping University.
Sferical AI aims to strengthen the competitiveness of Swedish industry by offering participating companies world-leading computing power for AI in an...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.08.25 - 14:03
|
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire)
|
|
|
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors.
Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President and CEO of CareDx, Inc., guiding the company through a period of rapid growth. He served as Chief Operating Officer at Ardelyx, where he built international partnerships to support commercialization, and held senior leadership roles at AstraZeneca, where he completed over 100 biologics transactions and managed portfolio strategy for more than 150 assets. His earlier career includes McKinsey & Company, Boehringer Ingelheim, and Organon.
Mr. Solari brings over 30 years of legal and financial experience in corporate gov...
|
|
|
|
|
|
|
06.08.25 - 22:06
|
IonQ Announces Second Quarter Financial Results (Business Wire)
|
|
|
Beats Top End Revenue Guidance by 15%
Announced $1.075 Billion Proposed Acquisition of Oxford Ionics, Enhancing Scalable Quantum Computing Breakthroughs
Completed Acquisition of Lightsynq and Capella, Substantially Accelerating Both Quantum Computing and Quantum Networking Roadmaps
Unanimously Appoints CEO Niccolo de Masi as next Chairman of the Board
Attracted Key Talent, Including Marco Pistoia as Senior Vice President of Industry Relations, Rick Muller as Vice President of Quantum Systems, and Paul Dacier as Chief Legal Officer
Achieved 20x Speed-Up in Quantum-Accelerated Drug Development with AstraZeneca, AWS, and NVIDIA
Pro-Forma Cash, Cash Equivalents, & Investments of $1.6 Billion as of July 9 After Closing $1 Billion Equity Offering
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the leading commercial quantum computing and networking company, today announced financial results for the quarter ended June 30, 2025.
"I am pleased to report that we beat the top end of guidance for Q2 reven...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
